News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,023 Results
Type
Article (14283)
Company Profile (105)
Press Release (259627)
Multimedia
Podcasts (68)
Webinars (13)
Section
Business (88280)
Career Advice (465)
Deals (15393)
Drug Delivery (74)
Drug Development (36726)
Employer Resources (50)
FDA (6385)
Job Trends (6233)
News (150722)
Policy (14131)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (14)
Adcomms (8)
Allergies (71)
Alliances (23317)
ALS (56)
Alzheimer's disease (480)
Antibody-drug conjugate (ADC) (101)
Approvals (6575)
Artificial intelligence (204)
Autoimmune disease (46)
Automation (13)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (120)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (174)
Cancer (1334)
Cardiovascular disease (154)
Career advice (418)
Career pathing (13)
CAR-T (53)
CDC (6)
Cell therapy (161)
Cervical cancer (9)
Clinical research (32042)
Collaboration (743)
Compensation (329)
Complete response letters (34)
COVID-19 (779)
CRISPR (45)
C-suite (449)
Cystic fibrosis (58)
Data (1843)
Denatured (18)
Depression (45)
Diabetes (127)
Diagnostics (1385)
Digital health (10)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (120)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (82)
Earnings (33510)
Editorial (21)
Employer branding (4)
Employer resources (46)
Events (39006)
Executive appointments (537)
FDA (7491)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (439)
Gene editing (73)
Generative AI (18)
Gene therapy (169)
GLP-1 (445)
Government (1406)
Grass and pollen (4)
Guidances (164)
Healthcare (3578)
HIV (12)
Huntington's disease (9)
IgA nephropathy (39)
Immunology and inflammation (69)
Immuno-oncology (15)
Indications (55)
Infectious disease (846)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (25)
Intellectual property (115)
Interviews (60)
IPO (5913)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (29)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3449)
Liver cancer (22)
Longevity (8)
Lung cancer (185)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (420)
MASH (74)
Medical device (1303)
Medtech (1310)
Mergers & acquisitions (9904)
Metabolic disorders (446)
Multiple sclerosis (48)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (38)
Neuroscience (894)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (602)
Now hiring (18)
Obesity (233)
Opinion (141)
Ovarian cancer (39)
Pain (110)
Pancreatic cancer (52)
Parkinson's disease (80)
Partnered (11)
Patents (224)
Patient recruitment (121)
Peanut (12)
People (29775)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8311)
Phase 2 (13528)
Phase 3 (12216)
Pipeline (1975)
Policy (136)
Postmarket research (1401)
Preclinical (3342)
Press Release (25)
Prostate cancer (86)
Psychedelics (17)
Radiopharmaceuticals (136)
Rare diseases (355)
Real estate (2659)
Recruiting (19)
Regulatory (10975)
Reports (15)
Research institute (575)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (70)
Series A (81)
Series B (53)
Service/supplier (2)
Sickle cell disease (47)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1646)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (48)
Vaccines (238)
Venture capital (33)
Weight loss (143)
Women's health (28)
Worklife (4)
Date
Last 7 days (212)
Last 30 days (682)
Last 365 days (10381)
2026 (1162)
2025 (10713)
2024 (12503)
2023 (14248)
2022 (19557)
2021 (20068)
2020 (19033)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15473)
2014 (12420)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (78)
Arkansas (3)
Asia (20908)
Australia (2689)
California (3205)
Canada (1499)
China (561)
Colorado (146)
Connecticut (133)
Delaware (126)
Europe (40908)
Florida (611)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (352)
India (45)
Indiana (241)
Iowa (2)
Japan (251)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (425)
Massachusetts (2621)
Michigan (46)
Minnesota (168)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1414)
New Mexico (7)
New York (912)
North Carolina (628)
North Dakota (2)
Northern California (1460)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (725)
Puerto Rico (13)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1403)
Tennessee (53)
Texas (457)
United States (12812)
Utah (60)
Virginia (161)
Washington D.C. (42)
Washington State (225)
West Virginia (1)
Wisconsin (39)
Wyoming (1)
274,023 Results for "madrigal pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
MASH
Madrigal Dives Further Into MASH With up to $4.4B siRNA Deal With Chinese Biotech
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
February 11, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
February 2, 2026
·
1 min read
Press Releases
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - February 5, 2026
February 6, 2026
·
1 min read
Press Releases
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - January 22, 2026
January 23, 2026
·
1 min read
Press Releases
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 16, 2025
·
1 min read
Press Releases
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) - January 21, 2026
January 22, 2026
·
1 min read
Press Releases
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
February 11, 2026
·
10 min read
Press Releases
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences - November 17, 2025
November 18, 2025
·
1 min read
Press Releases
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - December 18, 2025
December 19, 2025
·
1 min read
Press Releases
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
November 5, 2025
·
11 min read
1 of 27,403
Next
